Many patients who have stomach cancer are confused, wondering whether this disease can be treated and how to treat it. Gastric cancer is one of the most common malignant tumors in China, and the overall efficacy is still unsatisfactory, with an overall 5-year survival rate of only about 30%. There are still debates on the surgical approach, resection scope and whether to perform combined organ resection for gastric cancer. Modern radical surgery for gastric cancer includes adequate extent of gastrectomy, reasonable regional lymph node dissection and complete killing of abdominal free cancer cells, but many doctors do not pay enough attention to the treatment of abdominal exfoliated cells. In order to improve the overall survival rate of gastric cancer and to address these problems, we have conducted research on some key techniques of gastric cancer diagnosis and treatment from the basic to the clinical level over a period of 12 years with the support of a national “863” high-tech development program, two national natural science funds, a Shanghai natural science fund and a major science and technology project of Shanghai Science and Technology Commission. The research was carried out from basic to clinical level. We have achieved very good results and won the First Prize of Shanghai Science and Technology Progress. Through the above research, we have developed a set of more effective treatment plan for gastric cancer. First of all, preoperative staging, preoperative neoadjuvant chemotherapy for patients with late staging, through neoadjuvant chemotherapy can reduce the stage of tumor, that is to say, some patients with advanced stage can be reduced to middle or even early stage, so as to create conditions for further surgery. We have 2 patients, through 3 courses of neoadjuvant chemotherapy, no tumor tissue was found in the pathological examination of the resected specimens after surgery, which is very effective. Surgical treatment should emphasize the principle of tumor-free, and different surgical methods should be adopted for patients with different stages, i.e. to emphasize the thoroughness of surgical resection, and to avoid unnecessary trauma and risk to patients. In conclusion, surgery is a work of conscience, and not a good recovery of the patient after surgery is a good surgery. It is useless to have a good postoperative recovery if the resection is not complete for the sake of insurance and without principles. For middle and advanced gastric cancer cases, the main reasons for unsatisfactory treatment results and treatment failure are intra-abdominal recurrence and liver metastasis. Intra-abdominal recurrence is mainly caused by metastases in retroperitoneal lymph nodes and peritoneum as well as intra-abdominal dissemination of shed cancer cells. The ideal chemotherapy approach for GI tumors should be able to effectively target the common sites of recurrence and metastasis, such as resected areas, lymph node metastases, peritoneal implants, shed cells and liver. Then how to increase the concentration and prolong the duration of action of chemotherapeutic drugs in the abdominal cavity, lymph nodes, peritoneum and portal blood becomes the key to the success or failure of chemotherapy for gastric cancer. As a selective regional chemotherapy, intraperitoneal chemotherapy has obvious pharmacokinetic advantages over peripheral intravenous chemotherapy in killing free cancer cells in the abdominal cavity. Therefore, we believe that intraperitoneal chemotherapy should be given to all patients with intermediate to advanced disease, and should not be withheld for fear of risk and delay in surgery, because it is the only rare opportunity for patients to treat cancer cells shed from the abdominal cavity. Postoperative routine intravenous chemotherapy is equally important, and chemotherapy should be carried out according to internationally and nationally recognized protocols, not according to each doctor’s own preference, after all, one’s experience is limited. Although the treatment of gastric cancer is individualized, individualization is not arbitrary, and standardization should be the principle.